companies

CorWave

Founded 2012
Employees 60+
Primary contact
Equinox
19-21 allées de l'Europe
92110 Clichy
Île-de-France
France
+33(0)1 81 93 50 95
Links
https://www.corwave.com/
Diseases & Conditions
Sections
CorWave is a medical device company developing an implantable heart pump (Left Ventricular Assist Devices, LVADs) based on breakthrough technology, the wave membrane pump. The membrane is able to generate a natural pulse, replicating the blood flow and pressure characteristics of the patient's native heart. CorWave's novel membrane pump technology is being developed to reduce complications associated with current devices and improve the care of patients with heart failure.
Founded 2012
Employees 60+
Primary contact
Equinox
19-21 allées de l'Europe
92110 Clichy
Île-de-France
France
+33(0)1 81 93 50 95
Links
https://www.corwave.com/
Diseases & Conditions
Sections

Funding 💰

Total $81.1M
Last round 🔗 €35M
Series C
January 6, 2021.
Select investors Ysios Capital, Sofinnova Partners, Seventure Partners, Medtronic, Novo Holdings, Bpifrance, European Innovation Council, Arbevel

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Patented technology: CorWave's wave membrane pump was invented by Jean-Baptiste Drevet. It is the result of more than twenty years of research and development, and is capable of mimicking the native heart. This disruptive technology radically differentiates CorWave products from commercially-available rotary pump LVADs, and allows CorWave LVAD and Nemo to provide unique physiological blood flow.
  • CorWave LVAD: An LVAD with a unique, physiological behaviour. It is intended to treat patients with advanced heart failure, and aims to reduce the risk of complications associated with current LVADs. 🔗
  • Nemo: An implantable, minimally invasive cardiac pump designed to provide chronic, partial support to heart failure patients who are not eligible for LVADs and for whom there is currently no adequate treatment. 🔗
  • Media love: CorWave has been featured in a number of media outlets, including The Financial Times, Les Echos, Frankfurter Allgemeine Zeitung, Le Figaro, Die Zeit, La Tribune, and more. 🔗

Video ▶️

Awards & Recognitions 🏆

  • 2021 HealthTech Award 🔗
  • 2021 Part of the French Tech 120 index 🔗
  • 2019 Trophée de l'embarqué award for healthcare category
  • 2019 Selected among KPMG Tech Pulse 40 companies
  • 2018 Trophée des Futures Licornes: Nominee
  • 2017 Deloitte Technology Fast 50 Biotech Future Award 🔗

Quotes 💬

“
CorWave has built an international team of excellence that has achieved critical R&D milestones. The company is now in a very good position to seize a multi-billion-euro market opportunity. On behalf of the existing investors, I am very excited to continue to support CorWave in this new phase of growth.
— Gérard Hascoët, Chairman of the Board of Directors of CorWave and Venture Partner at Sofinnova Partners 🔗
Last update: January 13, 2023